Fig. 4.

Treatment with STING agonist increases CD103⁺ DC and activated CD8⁺ T cell infiltration in the TME of a mouse model of HGSC. Flow cytometry analysis of ID8-Trp53^−/− tumours treated with vehicle or STING agonist (day 55 after tumour injection and day 14 post STING agonist treatment) showing subset of CD103⁺ DCs (Panel a, CD11c⁺ gate) and CD69⁺/CD62L⁻ and PD-1⁺ TILs (Panel b, CD8⁺ gated). Mann–Whitney test was used to compare statistically significant differences between vehicle and STING agonist groups